TRPH-222 is under clinical development by Triphase Accelerator and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase I drugs for Diffuse Large B-Cell Lymphoma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TRPH-222’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TRPH-222 is under development for the treatment of relapsed and refractory B-Cell lymphoma including lymphoma, diffuse large b-cell lymphoma, follicular lymphoma, marginal zone b-cell lymphoma, acute lymphoblastic leukemia and mantle cell lymphoma. The therapeutic candidate is a modified humanized antibody conjugated to maytansine payload using Hydrazino-Pictet-Spengler (HIPS) chemistry and 4AP linker. It is administered through intravenous route. It targets cells expressing CD22 and is developed based on SMARTag technology.
Triphase Accelerator overview
Triphase Accelerator is a drug development company providing novel compounds for the treatment of cancer. The company’s pipeline products comprise marizomib, a brain-penetrant proteasome inhibitor, which is developed in both intravenous and oral formulations for the treatment of Glioblastoma; TRPH-222, a novel site-specific antibody-drug conjugate in development for lymphona; and TRPH-395 a novel small molecule inhibitor that disrupts WDR5 protein-protein interactions in solid tumors and hematological cancers. Triphase Accelerator is active in licensing oncology products of biotechnology, various educational institutions, and pharmaceutical companies. The company seeks to work in partnership with other companies and research institutions to advance its oncology drug candidates. The company has operations in Canada and the US. Triphase Accelerator is headquartered in Toronto, Ontario, Canada.
For a complete picture of TRPH-222’s drug-specific PTSR and LoA scores, buy the report here.